Association of ERCC1 Gene Polymorphisms (rs3212986 and rs11615) With the Risk of Lung Cancer in a Population From Southeast Iran
Open Access
- 30 September 2024
- journal article
- research article
- Published by Maad Rayan Publishing Company in Journal Of Research In Health Sciences
- Vol. 24 (4) , e00631
Abstract
Background: Polymorphisms within the excision repair cross-complementation group 1 (ERCC1), an essential component of DNA repair mechanisms, have been associated with various malignancies. This study aimed to evaluate the association of the single-nucleotide polymorphisms (SNPs) rs3212986 and rs11615 within the ERCC1 gene in non-small cell lung cancer (NSCLC) patients. Study Design: A case-control study. Methods: Genomic DNA was extracted from the peripheral blood samples of 83 NSCLC patients and 119 healthy individuals. The genetic diversity of SNPs rs3212986 and rs11615 was determined using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. The RFLP results were confirmed through sequencing. Results: The TT genotype of the rs11615 SNP was associated with a higher risk of NSCLC development (odds ratio: 3.900, 95% confidence interval: 0.603, 22.866, P=0.050). Furthermore, the AA genotype of rs3212986 was related to a higher risk of NSCLC development (OR: 2.531, 95% CI: 1.017, 6.300, P=0.046). A significant association was observed between smoking and lung cancer (OR: 3.072, 95% CI: 1.715, 5.503, P<0.001). Moreover, among non-smokers, there was an association between lung cancer risk and the AA (OR: 6.825, 95% CI: 1.722, 27.044, P=0.006) and AC (OR: 2.503, 95% CI: 0.977, 6.412, P=0.056) genotypes of rs3212986. However, no correlation was found between the genotypes of these SNPs and patients’ sensitivity to cisplatin and carboplatin (P ˃ 0.05). Conclusion: The rs11615-related TT genotype and the rs3212986-related AA genotype may be associated with a higher risk of lung cancer development.Keywords
This publication has 56 references indexed in Scilit:
- Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancerLung Cancer, 2013
- Polymorphisms in the ERCC1 and XPF Genes and Risk of Breast Cancer in a Chinese PopulationGenetic Testing and Molecular Biomarkers, 2013
- Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: A pooled analysis based on 39 reportsGene, 2013
- ERCC1 Expression Does Not Predict Survival and Treatment Response in Advanced Stage Non-Small Cell Lung Cancer Cases Treated with Platinum Based ChemotherapyAsian Pacific Journal of Cancer Prevention, 2013
- Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non-small cell lung cancer patientsOncology Reports, 2013
- The DNA damage response and cancer therapyNature, 2012
- Nucleotide excision repair gene ERCC1 polymorphisms contribute to cancer susceptibility: a meta-analysisMutagenesis, 2011
- The DNA Damage Response: Making It Safe to Play with KnivesMolecular Cell, 2010
- Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patientsLung Cancer, 2010
- Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapyCancer Treatment Reviews, 1998